Laiza Hombre Dias

Laiza Hombre Dias

Auto-generated profile, based on publicly available information

Laiza Hombre Dias

Secretaria de Estado da Saúde do Espírito Santo (SESA), Vitória 29050-260, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2021 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
LDLaiza Hombre Dias
Laiza Hombre Dias
SMSamira Tatiyama Miyamoto
Samira Tatiyama Miyamoto
RGRaquel Altoé Giovelli
Raquel Altoé Giovelli
CMCaerê Iamonde Maciel de Magalhães
Caerê Iamonde Maciel de Magalhães
VVValeria Valim
Valeria Valim
Background: Few studies have evaluated the relation of quality of life (QoL) with symptoms and disease activity in primary Sjögren’s syndrome (pSS). There is also scant information on the predictors of QoL in this population. The aim of this study was to assess QoL in patients with pSS and to investigate their possible predictors. Methods: In a cross-sectional study, 77 patients with pSS were evaluated using the following questionnaires: Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue), EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), Short Form-36 Health Survey (SF-36) and World Health Organization Quality of Life Assessment (WHOQOL-BREF). Seventy-seven healthy controls responded to the SF-36 and WHOQOL-BREF. The Mann-Whitney test, t-test, Pearson and Spearman correlation, and multiple regression analysis were used in the statistical analysis. Results: Patients with pSS and healthy controls were matched by gender and age. The mean scores for the ESSDAI, ESSPRI and FACIT-Fatigue were 3.34 ± 4.61, 6.58 ± 2.29 and 26.17 ± 11.02, respectively. Patients had a lower employment rate (36.4% versus 62.3%, p < 0.01) and higher work disability (10.4% versus 1.3%, p < 0.01). SF-36 and WHOQOL-BREF values were lower in patients with pSS (p < 0.001), except in the WHOQOL-BREF environment domain. Pain (ESSPRI), fatigue (FACIT-Fatigue), antinuclear antibody (ANA), anti-Ro-SSA and economic class (Brazilian Economic Classification Criteria - CCEB) were independent predictors of QoL. Conclusions: The main predictors of poor QoL in patients with pSS were pain and fatigue, and these symptoms had an impact regardless of disease activity, age, schooling, marital status, work disability and fibromyalgia.

2 January 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
SMSamira Tatiyama Miyamoto
Samira Tatiyama Miyamoto
VVValeria Valim
Valeria Valim
LCLuciana Carletti
Luciana Carletti
WNWan-Fai Ng
Wan-Fai Ng
APAnselmo José Perez
Anselmo José Perez
JNJamil Natour
Jamil Natour

3 May 2022 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
AGAna Paula Monteiro Gomides
Ana Paula Monteiro Gomides
CACleandro Pires de Albuquerque
Cleandro Pires de Albuquerque
LMLicia Maria Henrique Da Mota
Licia Maria Henrique Da Mota
GDGuilherme Devidé
Guilherme Devidé
LDLaiza Hombre Dias
Laiza Hombre Dias
OROn behalf of ReumaCoV Brasil Registry
On behalf of ReumaCoV Brasil Registry
Background: Patients using immunosuppressive drugs may have unfavorable results after infections. However, there is a lack of information regarding COVID-19 in these patients, especially in patients with rheumatoid arthritis (RA). Therefore, the aim of this study was to evaluate the risk factors associated with COVID-19 hospitalizations in patients with RA. Methods: This multicenter, prospective cohort study is within the ReumaCoV Brazil registry and included 489 patients with RA. In this context, 269 patients who tested positive for COVID-19 were compared to 220 patients who tested negative for COVID-19 (control group). All patient data were collected from the Research Electronic Data Capture database. Results: The participants were predominantly female (90.6%) with a mean age of 53 ± 12 years. Of the patients with COVID-19, 54 (20.1%) required hospitalization. After multiple adjustments, the final regression model showed that heart disease (OR = 4.61, 95% CI 1.06–20.02. P < 0.001) and current use of glucocorticoids (OR = 20.66, 95% CI 3.09–138. P < 0.002) were the risk factors associated with hospitalization. In addition, anosmia was associated with a lower chance of hospitalization (OR = 0.26; 95% CI 0.10–0.67, P < 0.005). Conclusion: Our results demonstrated that heart disease and the use of glucocorticoids were associated with a higher number of hospital admissions for COVID-19 in patients with RA. Trial registration: Brazilian Registry of Clinical Trials - RBR-33YTQC.

30 October 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
NMNésio Fernandes de Medeiros-Junior
Nésio Fernandes de Medeiros-Junior
MGMaria da Penha Gomes Gouvea
Maria da Penha Gomes Gouvea
LCLuiz Antônio Bastos Camacho
Luiz Antônio Bastos Camacho
DVDaniel A. M. Villela
Daniel A. M. Villela
SLSheila Barbosa Lima
Sheila Barbosa Lima
VVValeria Valim
Valeria Valim
Background: Dose-sparing approaches can be effective in maintaining immunogenicity and safety while expanding vaccine coverage. We previously demonstrated that a half dose of ChAdOx1 nCoV-19 is as effective and immunogenic for primary vaccination. Methods: This non-inferiority, non-randomized controlled trial evaluated the effectiveness, humoral, and cellular immune responses of a third booster dose—comparing half-dose and full-dose regimens—in individuals aged 18–49 years, with a 1-year follow-up. Results: A total of 2801 participants were enrolled: 2352 received half doses and 449 received full doses. The incidence rate of COVID-19 was 225.0 per 1000 person-years in the half-dose group and 173.8 in the full-dose group, with no significant difference in effectiveness (β = −0.05; 95% CrI: −0.24 to 0.15). No deaths occurred, and hospitalization rates were similar. In a subsample (n = 558), anti-S IgG levels peaked 28 days post-dose and declined by day 180 after the primary series [175 (121–252) vs. 121 (71–208) GMT, p < 0.001], but remained elevated after the booster [192.1 (124–297) vs. 550 (380–797) GMT, p < 0.001]. Booster antibody levels were similar between groups [592.4 (318–1140) vs. 550 (380–797) GMT]. The half-dose group showed high titers against Omicron and robust T/B-cell responses (e.g., EMCD4, EMCD8, IFN+CD4+, CD19+TNF+). Conclusions: Fractional half dose of ChAdOx nCov-19 was effective and non-inferior to a full booster dose. Homologous regimen with 3 half doses or 3 full doses induced a similar increase in antibody titers and robust cellular response. ClinicalTrials.gov (NCT05059106).

1 January 2023
Verified
Conference Paper
Open access
JAJoão Pedro de Matos Assunção
João Pedro de Matos Assunção
GRGUSTAVO Gomes RESENDE
GUSTAVO Gomes RESENDE
AKAdriana Maria Kakehasi
Adriana Maria Kakehasi
SRSandra Lúcia Euzébio Ribeiro
Sandra Lúcia Euzébio Ribeiro
JSJuliana Alves Scrignoli
Juliana Alves Scrignoli
GFGilda Aparecida Ferreira
Gilda Aparecida Ferreira